Unintended effects of statins from observational studies in the general population: Systematic review and meta-analysis

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Macedo, Ana F ^a,b   Taylor, Fiona C ^a   Casas, Juan P ^a,c   Adler, Alma ^a   Prieto Merino, David ^a   Ebrahim, Shah ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Meta analysis; Observational studies; Statins; Systematic review; Unintended effects

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME;

ADVERSE DRUG REACTION; ARTICLE; BRAIN HEMORRHAGE; CATARACT; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; EPISODIC MEMORY; EYE DISEASE; FOLLOW UP; FRACTURE; GALLSTONE; GLAUCOMA; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; META ANALYSIS; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PNEUMONIA; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

DEMENTIA; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OBSERVATIONAL STUDY AS TOPIC; POPULATION SURVEILLANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84899150858     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-51     Document Type: Article

References (142)

1. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, 1. CD004816.
2. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999, 159:1793-1802. 10.1001/archinte.159.15.1793, 10448784.
3. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Int Med 2006, 166:2307-2313.
4. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004, 117:596-606. 10.1016/j.amjmed.2004.04.022, 15465509.
5. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346. 10.1001/jama.282.24.2340, 10612322.
6. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997, 278:313-321. 10.1001/jama.1997.03550040069040, 9228438.
7. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009, 169:1756-1761.
8. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R., Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Erratum in: Lancet 2005, 366:1358. Lancet 2008, 371:2084, Cholesterol Treatment Trialists' (CTT) Collaborators.
9. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R., Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. 2988224, 21067804, Cholesterol Treatment Trialists' (CTT) Collaboration.
10. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C., Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. 3437972, 22607822, Cholesterol Treatment Trialists' (CTT) Collaborators.
11. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C., Cholesterol Treatment Trialists' (CTT) Collaboration Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012, 7:e29849. 10.1371/journal.pone.0029849, 3261846, 22276132, Cholesterol Treatment Trialists' (CTT) Collaboration.
12. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742. 10.1016/S0140-6736(09)61965-6, 20167359.
13. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011, 104:109-124. 10.1093/qjmed/hcq165, 20934984.
14. FDA expands advice on statin risks. [http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm].
15. Statins: risk of hyperglycaemia and diabetes. Drug safety update January 2012. 5:A2. [http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON140667].
16. Feng L, Yap KB, Kua EH, Ng TP. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol Drug Saf 2010, 19:942-948. 10.1002/pds.1993, 20575082.
17. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003, 163:1926-1932. 10.1001/archinte.163.16.1926, 12963565.
18. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, van Belle G, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004, 63:1624-1628. 10.1212/01.WNL.0000142963.90204.58, 15534246.
19. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, Kuller L., Cardiovascular Health Study Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005, 65:1388-1394. 10.1212/01.wnl.0000182897.18229.ec, 16275825, Cardiovascular Health Study.
20. McGwin G, Modjarrad K, Andrew Hal T, Xie A, Owsley C. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the cardiovascular health study. Arch Ophthalmol 2006, 124:33-37. 10.1001/archopht.124.1.33, 16401782.
21. McCarty CA, Mukesh BN, Guymer RH, Baird PN, Taylor HR. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Med J Aust 2001, 175:340.
22. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease and dementia. Cochrane Database Syst Rev 2001, CD003160.
23. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev 2010, CD007514.
24. Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration. Cochrane Database Syst Rev 2012, CD006927.
25. Wang J, Xiao Y, Luo M, Luo H. Statins for multiple sclerosis. Cochrane Database Syst Rev 2011, CD008386.
26. Li L, Sun T, Zhang P, Tian J, Yang K. Statins for primary prevention of venous thromboembolism. Cochrane Database Syst Rev 2011, CD008203.
27. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW., PROSPER Executive Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011, 342:d1250. 10.1136/bmj.d1250, 21411487, PROSPER Executive.
28. Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R., Heart Protection Study Collaborative Group Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011, 378:2013-2020. 3242163, 22115874, Heart Protection Study Collaborative Group.
29. ClinicalEvidence: Learn, teach, and practise evidence-based medicine. [http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665076.html].
30. Golder S, Loke YK. Sensitivity and precision of adverse effects search filters in MEDLINE and EMBASE: a case study of fractures with thiazolidinediones. Health Info Libr J 2012, 29:28-38. 10.1111/j.1471-1842.2011.00972.x, 22335287.
31. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 [updated September 2009]. The Cochrane Collaboration 2009, Chichester, UK: John Wiley & Sons, Ltd, [http://www.cochrane-handbook.org].
32. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997, 315:1533-1537. 10.1136/bmj.315.7121.1533, 2127925, 9432252.
33. Anderson JL, Muhlestein JB, Bair TL, Morris S, Weaver AN, Lappé DL, Renlund DG, Pearson RR, Jensen KR, Horne BD. Do statins increase the risk of idiopathic polyneuropathy?. Am J Cardiol 2005, 95:1097-1099. 10.1016/j.amjcard.2004.12.068, 15842981.
34. Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C, Aihie Sayer A. Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. Age Ageing 2010, 39:185-191. 10.1093/ageing/afp203, 3546312, 20019032.
35. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, de Jong PE, de Jong-van den Berg LT., PREVEND study group The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006, 21:3106-3114. 10.1093/ndt/gfl244, 16720593, PREVEND study group.
36. Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf 2008, 31:399-407. 10.2165/00002018-200831050-00004, 18422380.
37. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000, 355:2185-2188. 10.1016/S0140-6736(00)02400-4, 10881890.
38. Clockaerts S, Van Osch GJ, Bastiaansen-Jenniskens YM, Verhaar JA, Van Glabbeek F, Van Meurs JB, Kerkhof HJ, Hofman A, Stricker BH, Bierma-Zeinstra SM. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012, 71:642-647. 10.1136/annrheumdis-2011-200092, 21989540.
39. Corrao G, Zambon A, Bertù L, Botteri E, Leoni O, Contiero P. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. J Epidemiol Community Health 2004, 58:1047-1051. 10.1136/jech.2003.013409, 1732626, 15547071.
40. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008, 71:344-350. 10.1212/01.wnl.0000319647.15752.7b, 2676946, 18663180.
41. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012, 172:144-152. 10.1001/archinternmed.2011.625, 22231607.
42. de Jong HJ, Klungel OH, van Dijk L, Vandebriel RJ, Leufkens HG, van der Laan JW, Cohen Tervaert JW, van Loveren H. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012, 71:648-654. 10.1136/ard.2011.155622, 21979000.
43. de Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 2006, 35:1301-1308. 10.1093/ije/dyl147, 17053011.
44. Doggen CJ, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM. HMG CoA reductase inhibitors and the risk of venous thrombosis among post-menopausal women. J Thromb Haemost 2004, 2:700-701. 10.1111/j.1538-7836.2004.00696.x, 15099273.
45. Erichsen R, Frøslev T, Lash TL, Pedersen L, Sorensen HT. Long-term statin use and the risk of gallstone disease: a population-based case-control study. Am J Epidemiol 2011, 173:162-170. 10.1093/aje/kwq361, 21084557.
46. Fleming DM, Verlander NQ, Elliot AJ, Zhao H, Gelb D, Jehring D, Nguyen-Van-Tam JS. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect 2010, 138:1281-1288. 10.1017/S0950268810000105, 20109259.
47. Fujii T, Nakabayashi T, Hashimoto S, Kuwano H. Statin use and risk of gastroduodenal ulcer and reflux esophagitis. Hepatogastroenterology 2009, 56:641-644.
48. Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?. Eur J Clin Pharmacol 2001, 56:931-933. 10.1007/s002280000248, 11317483.
49. Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002, 58:1333-1337. 10.1212/WNL.58.9.1333, 12011277.
50. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001, 12:565-569. 10.1097/00001648-200109000-00017, 11505177.
51. Gao X, Simon K, Schwarzschild MA, Ascherio A. A prospective study of statin use and risk of Parkinson disease. Parkinsonism Relat D 2012, 18:S40.
52. Green RC, McNagny SE, Jayakumar P, Cupples LA, Benke K, Farrer LA., MIRAGE Study Group Statin use and the risk of Alzheimer's disease: the MIRAGE study. Alzheimers Dement 2006, 2:96-103. 10.1016/j.jalz.2006.02.003, 19595865, MIRAGE Study Group.
53. Gulmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, Hansen JM, Andersen M, Hallas J. Do statins protect against upper gastrointestinal bleeding?. Br J Clin Pharmacol 2009, 67:460-465. 10.1111/j.1365-2125.2009.03362.x, 2679110, 19371320.
54. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009, 80:13-17. 10.1136/jnnp.2008.150433, 18931004.
55. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010, 340:c2197. 10.1136/bmj.c2197, 2874131, 20488911.
56. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord 2007, 22:377-381. 10.1002/mds.21290, 1906875, 17177184.
57. Huerta C, Johansson S, Wallander MA, Garci{dotless}a Rodri{dotless}guez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007, 167:935-943. 10.1001/archinte.167.9.935, 17502535.
58. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000, 356:1627-1631. 10.1016/S0140-6736(00)03155-X, 11089820.
59. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 2004, 58:303-309. 10.1111/j.1365-2125.2004.02142.x, 1884569, 15327590.
60. Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009, 68:546-551. 10.1136/ard.2008.091967, 18662929.
61. Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA 2006, 295:2752-2758. 10.1001/jama.295.23.2752, 16788130.
62. Klein R, Klein BE, Tomany SC, Danforth LG, Cruickshanks KJ. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003, 121:1151-1155. 10.1001/archopht.121.8.1151, 12912693.
63. Klein R, Knudtson MD, Klein BE. Statin use and the five-year incidence and progression of age-related macular degeneration. Am J Ophthalmol 2007, 144:1-6. 10.1016/j.ajo.2007.02.047, 1988696, 17475196.
64. Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 2009, 4:e8087. 10.1371/journal.pone.0008087, 2778952, 19956645.
65. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, Jackson RD. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003, 139:97-104. 10.7326/0003-4819-139-2-200307150-00009, 12859159.
66. LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Newman AB, Kooperberg CL, Black H, Curb JD, Greenland P, Woods NF. Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci 2008, 63:369-375. 10.1093/gerona/63.4.369, 18426960.
67. Lacut K, Le Gal G, Abalain JH, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thromb Res 2008, 122:314-319. 10.1016/j.thromres.2007.10.014, 18048086.
68. Lemaitre RN, Psaty BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 2002, 162:1395-1400. 10.1001/archinte.162.12.1395, 12076239.
69. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 2010, 58:1311-1317. 10.1111/j.1532-5415.2010.02906.x, 3176730, 20533968.
70. Luijendijk HJ, Stricker BH, Hofman A, Witteman JCM, Tiemeier H. Cerebrovascular risk factors and incident depression in community-dwelling elderly. Acta Psychiatr Scand 2008, 118:139-148. 10.1111/j.1600-0447.2008.01189.x, 18452572.
71. Marcus MW, Müskens RP, Ramdas WD, Wolfs RC, De Jong PT, Vingerling JR, Hofman A, Stricker BH, Jansonius NM. Cholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort study. PLoS ONE 2012, 7:e29724. 10.1371/journal.pone.0029724, 3251600, 22238644.
72. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol 2007, 60:812-818. 10.1016/j.jclinepi.2006.11.006, 17606177.
73. McGwin G, Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. Br J Ophthalmol 2003, 87:1121-1125. 10.1136/bjo.87.9.1121, 1771871, 12928279.
74. McGwin G, McNeal S, Owsley C, Girkin C, Epstein D, Lee PP. Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol 2004, 122:822-826. 10.1001/archopht.122.6.822, 15197056.
75. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205-3210. 10.1001/jama.283.24.3205, 10866867.
76. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009, 18:269-275. 10.1002/pds.1715, 19235776.
77. Nash SD, Cruickshanks KJ, Klein R, Klein BE, Nieto FJ, Huang GH, Pankow JS, Tweed TS. The prevalence of hearing impairment and associated risk factors: the Beaver Dam Offspring Study. Arch Otolaryngol Head Neck Surg 2011, 137:432-439. 10.1001/archoto.2011.15, 3096733, 21339392.
78. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007, 29:1761-1770. 10.1016/j.clinthera.2007.08.022, 17919557.
79. Owen CG, Carey IM, Shah S, de Wilde S, Wormald R, Whincup PH, Cook DG. Hypotensive medication, statins, and the risk of glaucoma. Invest Ophthalmol Vis Sci 2010, 51:3524-3530. 10.1167/iovs.09-4821, 20130286.
80. Ramcharan AS, van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors are associated with a reduced risk of venous thrombosis. J Thromb Haemost 2009, 7:514-520. 10.1111/j.1538-7836.2008.03235.x, 19036068.
81. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002, 8:276-279. 10.1136/ip.8.4.276, 1756571, 12460961.
82. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005, 62:1047-1051. 10.1001/archneur.62.7.1047, 16009757.
83. Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sørensen HT, Mosekilde L. Hip fracture risk in statin users-a population-based Danish case-control study. Osteoporos Int 2004, 15:452-458.
84. Risselada R, Straatman H, van Kooten F, Dippel DW, van der Lugt A, Niessen WJ, Firouzian A, Herings RM, Sturkenboom MC. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke 2009, 40:2887-2892. 10.1161/STROKEAHA.109.552760, 19520985.
85. Ritz B, Manthripragada AD, Qian L, Schernhammer E, Wermuth L, Olsen J, Friis S. Statin use and Parkinson's disease in Denmark. Mov Disord 2010, 25:1210-1216. 10.1002/mds.23102, 2910157, 20629142.
86. Rockwood K, Howlett S, Fisk J, Darvesh S, Tuokko H, Hogan DB, Wolfson C, McDowell I. Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. Neuroepidemiology 2007, 29:201-207. 10.1159/000111583, 18043005.
87. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002, 59:223-227. 10.1001/archneur.59.2.223, 11843693.
88. Rodríguez GL, Wallander MA, Tolosa LB, Johansson S. Chronic obstructive pulmonary disease in UK primary care: incidence and risk factors. COPD 2009, 6:369-379. 10.1080/15412550903156325, 19863366.
89. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007, 27:325-332. 10.1592/phco.27.3.325, 17316144.
90. Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med 2001, 161:2021-2026. 10.1001/archinte.161.16.2021, 11525705.
91. Schoofs MW, Sturkenboom MC, van der Klift M, Hofman A, Pols HA, Stricker BH. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 2004, 19:1525-1530. 10.1359/JBMR.040607, 15312254.
92. Scranton RE, Young M, Lawler L, Solomon DH, Gagnon DR, Gaziano JM. Statin use and fracture risk: study of a US veterans population. Arch Intern Med 2005, 165:2007-2012. 10.1001/archinte.165.17.2007, 16186471.
93. Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE. A case control study of age related macular degeneration and use of statins. Br J Ophthalmol 2005, 89:1171-1175. 10.1136/bjo.2004.064477, 1772815, 16113375.
94. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009, 67:99-109. 10.1111/j.1365-2125.2008.03308.x, 2668090, 19006546.
95. Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM 2003, 96:337-343. 10.1093/qjmed/hcg064, 12702782.
96. Solomon A, Kåreholt I, Ngandu T, Wolozin B, MacDonald SW, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging 2009, 30:1006-1009. 10.1016/j.neurobiolaging.2007.09.012, 18022292.
97. Sørensen HT, Horvath-Puho E, Søgaard KK, Christensen S, Johnsen SP, Thomsen RW, Prandoni P, Baron JA. Arterial cardiovascular events, statins, low dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009, 7:521-528. 10.1111/j.1538-7836.2009.03279.x, 19192118.
98. Sørensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes 2010, 3:413-417. 10.1161/CIRCOUTCOMES.110.936278, 20530788.
99. St Sauver JL, Jacobsen SJ, Jacobson DJ, McGree ME, Girman CJ, Girman CJ, Nehra A, Roger VL, Lieber MM. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int 2011, 107:443-450. 10.1111/j.1464-410X.2010.09598.x, 2997141, 20804476.
100. Sukhija R, Bursac Z, Kakar P, Fink L, Fort C, Satwani S, Aronow WS, Bansal D, Mehta JL. Effect of statins on the development of renal dysfunction. Am J Cardiol 2008, 101:975-979. 10.1016/j.amjcard.2007.11.042, 18359317.
101. Szwast SJ, Hendrie HC, Lane KA, Gao S, Taylor SE, Unverzagt F, Murrell J, Deeg M, Ogunniyi A, Farlow MR, Hall KS. Association of statin use with cognitive decline in elderly African Americans. Neurology 2007, 69:1873-1880. 10.1212/01.wnl.0000279333.77404.d7, 2857758, 17984456.
102. Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol 2007, 143:687-689. 10.1016/j.ajo.2006.11.027, 17386279.
103. Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statins and the long-term risk of incident age-related macular degeneration: the Blue Mountains Eye Study. Am J Ophthalmol 2007, 143:685-687. 10.1016/j.ajo.2006.11.021, 17386278.
104. Tsai C-J, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009, 136:1593-1600. 10.1053/j.gastro.2009.01.042, 3668330, 19208351.
105. van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003, 326:255-256. 10.1136/bmj.326.7383.255, 140763, 12560276.
106. van Leeuwen R, Tomany SC, Wang JJ, Klein R, Mitchell P, Hofman A, Klein BE, Vingerling JR, Cumming RG, de Jong PT. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology 2004, 111:1169-1175. 10.1016/j.ophtha.2003.10.024, 15177967.
107. van Staa T, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001, 285:1850-1855. 10.1001/jama.285.14.1850, 11308398.
108. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology 2008, 70:1418-1422. 10.1212/01.wnl.0000286942.14552.51, 3690297, 18184918.
109. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000, 283:3211-3216. 10.1001/jama.283.24.3211, 10866868.
110. Woo D, Kissela BM, Khoury JC, Sauerbeck LR, Haverbusch MA, Szaflarski JP, Gebel JM, Pancioli AM, Jauch EC, Schneider A, Kleindorfer D, Broderick JP. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 2004, 35:1360-1364. 10.1161/01.STR.0000127786.16612.A4, 15087556.
111. Yang C-C, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 2002, 53:101-105. 10.1046/j.0306-5251.2001.01523.x, 1874555, 11849201.
112. Yang CC, Kao CC. Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case-control study. J Chin Med Assoc 2007, 70:103-109. 10.1016/S1726-4901(09)70339-9, 17389154.
113. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004, 23:94-98. 10.1159/000073981, 14739574.
114. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC., Cache County Study investigators Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005, 62:217-224. 10.1001/archpsyc.62.2.217, 15699299, Cache County Study investigators.
115. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011, 8:e1001026. 10.1371/journal.pmed.1001026, 3086872, 21559325.
116. O'Neil A, Sanna L, Redlich C, Sanderson K, Jacka F, Williams LJ, Pasco JA, Berk M. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012, 10:154. 10.1186/1741-7015-10-154, 3568015, 23206308.
117. Toh S, Hernández-Díaz S. Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 2007, 16:627-640. 10.1002/pds.1363, 17286319.
118. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006, 17:2006-2016. 10.1681/ASN.2006010012, 16762986.
119. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, Robertson M, Wikstrand J, McMurray J. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012, 9:e1001310. 10.1371/journal.pmed.1001310, 3445446, 23028261.
120. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013, 88:1213-1221. 10.1016/j.mayocp.2013.07.013, 24095248.
121. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, de Goma EM. Statins and cognitive function: a systematic review. Ann Int Med 2013, 159:688-697. 10.7326/0003-4819-159-10-201311190-00007, 24247674.
122. Kwok CS, Yeong JK, Turner RM, Cavallazzi R, Singh S, Loke YK. Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies. Eur J Clin Pharmacol 2012, 68:747-755. 10.1007/s00228-011-1159-4, 22083167.
123. Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn R, Ridker PM. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ 2012, 184:E367-E372. 10.1503/cmaj.111017, 3328541, 22431901.
124. Chopra V, Flanders SA. Does statin use improve pneumonia outcomes?. Chest 2009, 136:1381-1388. 10.1378/chest.09-0941, 19892677.
125. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564. 10.1001/jama.2011.860, 21693744.
126. Waters DD, Ho JE, de Micco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011, 57:1535-1545. 10.1016/j.jacc.2010.10.047, 21453832.
127. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013, 346:f2610. 10.1136/bmj.f2610, 3662830, 23704171.
128. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571. 10.1016/S0140-6736(12)61190-8, 3774022, 22883507.
129. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006, 49:1881-1892. 10.1007/s00125-006-0269-5, 16685502.
130. Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, Brunham LR, Verchere CB, Hayden MR. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010, 53:1110-1119. 10.1007/s00125-010-1691-2, 20229095.
131. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011, 215:1-8. 10.1016/j.atherosclerosis.2010.10.036, 21130454.
132. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006, 97:52C-60C.
133. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation 2013, 127:96-103. 10.1161/CIRCULATIONAHA.112.136101, 23183941.
134. Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA 2013, 173:1-10.
135. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Int Med 2012, 157:263-275. 10.7326/0003-4819-157-4-201208210-00007, 3955032, 22910937.
136. Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Int Med 2012, 157:251-262. 10.7326/0003-4819-157-4-201208210-00005, 22910936.
137. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790. 10.1016/S0140-6736(07)60716-8, 17559928.
138. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013, 6:390-399. 10.1161/CIRCOUTCOMES.111.000071, 23838105.
139. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011, 124:2233-2242. 10.1161/CIRCULATIONAHA.111.055269, 22007076.
140. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013, 10:453-464. 10.1038/nrcardio.2013.80, 23736519.
141. van Staa TJ, Smeeth L, Ng ES, Goldacre B, Gulliford M. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?. Heart 2013, 99:1597-1602. 10.1136/heartjnl-2013-303698, 3812879, 23735939.
142. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010, 122:2078-2088. 10.1161/CIRCULATIONAHA.109.873232, 21098469.